Frequent expression loss of Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: A systematic expression analysis

Table 5 Clinicopathological and immunohistochemical parameters in relation to cytoplasmic ITIH2 immunoreactivity

Variable	Categorization	ITIH2 immunoreactivity				Tumor-related death			Tumor recurrence
		n analyzable	weak	strong	p³	n	events	p⁴	n	events	p⁴
*Clinicopathological factor:*
Tumor stage¹
	pT1	46	19	27	0.875	46	7	<0.001	45	10	<0.001
	pT2	92	43	49		92	32		89	41
	pT3	13	5	8		13	6		12	6
	pT4	30	12	18		30	19		27	19
Lymph node status¹
	pN0	71	30	41	0.757	71	12	<0.001	69	14	<0.001
	pN1–3	104	47	57		104	47		100	57
Histological grade
	low grade (G1 – G2)	100	40	60	1.000	100	26	<0.001	95	33	<0.001
	high grade (G3)	80	38	42		80	38		78	42
Histological type
	ductal	145	61	84	0.915	145	51	0.772	142	65	0.371
	lobular	13	5	8		13	6		11	4
	other	19	9	10		19	6		17	5
*Immunohistochemistry (IHC):*
Estrogen receptor status
	negative (IRS² 0–2)	49	30	19	0.001	49	21	0.080	49	25	0.096
	positive (IRS 3–12)	97	31	66		97	29		93	33
Progesterone receptor status
	negative (IRS² 0–2)	107	44	63	0.862	107	48	0.001	101	50	0.008
	positive (IRS 3–12)	49	21	28		49	9		49	13
HER2 expression status
	negative	120	53	67	0.190	120	33	<0.001	113	43	0.007
	positive	38	12	26		38	22		38	22

P-values according to Fisher's exact test (two-sided) were calculated for significance of correlation between clinicopathological and immunohistochemical parameters in relation to cytoplasmatic ITIH2 immunoreactivity. Furthermore, univariate analysis of factors regarding tumor-specific survival and recurrence-free survival was performed with significance calculated by log rank test (two-sided).
¹According to UICC: TNM Classification of Malignant Tumours (2002) [65]. ²IRS = Immunoreactivity score according to Remmele and Stegner (1987) [47]. ³Fisher's exact test (two-sided). ⁴Log-rank test (two-sided). Bold face representing significant data (p < 0.05).

ISSN: 1471-2407